Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Furst

Showing results (391-400 of 477) with videos related to

Pageof 48
Sort By:
The Journal of Rheumatology|August 17, 2017
Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop ReportSusan J Bartlett, Skye P Barbic, Vivian P Bykerk, et al.
Rheumatology (Oxford, England)|October 28, 2017
Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosisMichael B Arnold, Dinesh Khanna, Christopher P Denton, et al.
The Journal of Rheumatology|August 4, 2004
Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trialJoel Kremer, Mark Genovese, Grant W Cannon, et al.
The Journal of Rheumatology|May 3, 2017
An OMERACT Initiative Toward Consensus to Identify and Characterize Candidate Contextual Factors: Report from the Contextual Factors Working GroupMonika E Finger, Annelies Boonen, Thasia G Woodworth, et al.
Annals of the Rheumatic Diseases|February 7, 2012
Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registrySangmee Bae, Rajeev Saggar, Marcy B Bolster, et al.
The Journal of Rheumatology|May 4, 2005
Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trialDinesh Khanna, Daniel E Furst, Philip J Clements, et al.
Seminars in Arthritis and Rheumatism|January 23, 2021
Harms reported by patients in rheumatology drug trials: a systematic review of randomized trials in the cochrane library from an OMERACT working groupDorthe B Berthelsen, Thasia G Woodworth, Niti Goel, et al.
Rheumatology (Oxford, England)|December 28, 2018
Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritisJeffrey R Curtis, Darl D Flake, Michael E Weinblatt, et al.
Arthritis and Rheumatism|April 29, 2008
Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trialPeter A Merkel, Nancy P Silliman, Christopher P Denton, et al.
Arthritis and Rheumatism|June 3, 2008
A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase diseaseArnold E Postlethwaite, Weng Kee Wong, Philip Clements, et al.
Pageof 48

Showing results (391-400 of 477) with videos related to

Sort By:
Pageof 48
The Journal of Rheumatology|August 17, 2017
Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop ReportSusan J Bartlett, Skye P Barbic, Vivian P Bykerk, et al.
Rheumatology (Oxford, England)|October 28, 2017
Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosisMichael B Arnold, Dinesh Khanna, Christopher P Denton, et al.
The Journal of Rheumatology|August 4, 2004
Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trialJoel Kremer, Mark Genovese, Grant W Cannon, et al.
The Journal of Rheumatology|May 3, 2017
An OMERACT Initiative Toward Consensus to Identify and Characterize Candidate Contextual Factors: Report from the Contextual Factors Working GroupMonika E Finger, Annelies Boonen, Thasia G Woodworth, et al.
Annals of the Rheumatic Diseases|February 7, 2012
Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registrySangmee Bae, Rajeev Saggar, Marcy B Bolster, et al.
The Journal of Rheumatology|May 4, 2005
Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trialDinesh Khanna, Daniel E Furst, Philip J Clements, et al.
Seminars in Arthritis and Rheumatism|January 23, 2021
Harms reported by patients in rheumatology drug trials: a systematic review of randomized trials in the cochrane library from an OMERACT working groupDorthe B Berthelsen, Thasia G Woodworth, Niti Goel, et al.
Rheumatology (Oxford, England)|December 28, 2018
Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritisJeffrey R Curtis, Darl D Flake, Michael E Weinblatt, et al.
Arthritis and Rheumatism|April 29, 2008
Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trialPeter A Merkel, Nancy P Silliman, Christopher P Denton, et al.
Arthritis and Rheumatism|June 3, 2008
A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase diseaseArnold E Postlethwaite, Weng Kee Wong, Philip Clements, et al.
Pageof 48